Incidence and risk of denosumab-related hypocalcemia in cancer patients: a systematic review and pooled analysis of randomized controlled studies

References

• Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001;27:165-76
   PubMed Web of Science ®Google Scholar
• Aapro MS. Denosumab for bone metastases from breast cancer: a new therapy option? J Clin Oncol 2011;29:e419-20; author reply e21-4
   PubMed Web of Science ®Google Scholar
• Weinfurt KP, Li Y, Castel LD, et al. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol 2005;16:579-84
   PubMed Web of Science ®Google Scholar
• Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94:1458-68
   PubMed Web of Science ®Google Scholar
• Qi WX, Tang LN, He AN, et al. The role of vandetanib in the second-line treatment for advanced non-small-cell-lung cancer: a meta-analysis of four randomized controlled trials. Lung 2011;189:437-43
   PubMed Web of Science ®Google Scholar
• Qi WX, Tang LN, He AN, et al. Erlotinib and pemetrexed as maintenance therapy for advanced non-small-cell lung cancer: a systematic review and indirect comparison. Curr Med Res Opin 2012;28:643-50
   PubMed Web of Science ®Google Scholar
• Su Y, Yang WB, Li S, et al. Effect of angiogenesis inhibitor bevacizumab on survival in patients with cancer: a meta-analysis of the published literature. PLoS One 2012;7:e35629
   PubMedGoogle Scholar
• Qi WX, Shen Z, Lin F, et al. Overall survival benefits for irinotecan-containing regimens as first-line treatment for advanced gastric cancer: an updated meta-analysis of ten randomized controlled trials. Int J Cancer 2013;132:E66-73
   PubMed Web of Science ®Google Scholar
• Qi WX, Wang Q, Jiang YL, et al. Overall survival benefits for combining targeted therapy as second-line treatment for advanced non-small-cell-lung cancer: a meta-analysis of published data. PLoS One 2013;8:e55637
   PubMed Web of Science ®Google Scholar
• Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004;350:1655-64
   PubMed Web of Science ®Google Scholar
• Theriault RL. Biology of bone metastases. Cancer Control 2012;19:92-101
   PubMed Web of Science ®Google Scholar
• Bundred N. Antiresorptive therapies in oncology and their effects on cancer progression. Cancer Treat Rev 2012;38:776-86
   PubMed Web of Science ®Google Scholar
• Smith MR, Saad F, Coleman R, et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 2012;379:39-46
   PubMed Web of Science ®Google Scholar
• Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010;28:5132-9
   PubMed Web of Science ®Google Scholar
• Reddy GK, Mughal TI, Roodman GD. Novel approaches in the management of myeloma-related skeletal complications. Support Cancer Ther 2006;4:15-18
   PubMedGoogle Scholar
• Peddi P, Lopez-Olivo MA, Pratt GF, et al. Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis. Cancer Treat Rev 2013;39:97-104
   PubMed Web of Science ®Google Scholar
• Brown-Glaberman U, Stopeck AT. Role of denosumab in the management of skeletal complications in patients with bone metastases from solid tumors. Biologics 2012;6:89-99
   PubMedGoogle Scholar
• Tabrizi MA, Tseng CM, Roskos LK. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today 2006;11:81-8
   PubMed Web of Science ®Google Scholar
• Miller PD, Bolognese MA, Lewiecki EM, et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 2008;43:222-9
   PubMed Web of Science ®Google Scholar
• Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011;29:1125-32
   PubMed Web of Science ®Google Scholar
• Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011;377:813-22
   PubMed Web of Science ®Google Scholar
• Khan A, Fong J. Hypocalcemia: updates in diagnosis and management for primary care. Can Fam Physician 2012;58:158-62
   PubMed Web of Science ®Google Scholar
• NCI, Cancer Therapy Evaluation Program. CTC v 2.0 and common terminology criteria for adverse events criteria V3.0 (CTCAE). Available at: http://ctepcancergov/protocolDevelopment/electronic_applications/ctchtm [Last accessed 27 January 2013]
   Google Scholar
• Choueiri TK, Schutz FA, Je Y, et al. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol 2010;28:2280-5
   PubMed Web of Science ®Google Scholar
• Zintzaras E, Ioannidis JP. Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol 2005;28:123-37
   PubMed Web of Science ®Google Scholar
• Yusuf S, Peto R, Lewis J, et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985;27:335-71
   PubMed Web of Science ®Google Scholar
• Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088-101
   PubMed Web of Science ®Google Scholar
• Smith MR, Egerdie B, Hernandez Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009;361:745-55
   PubMed Web of Science ®Google Scholar
• Fizazi K, Lipton A, Mariette X, et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 2009;27:1564-71
   PubMed Web of Science ®Google Scholar
• Ellis GK, Bone HG, Chlebowski R, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 2008;26:4875-82
   PubMed Web of Science ®Google Scholar
• Shoback D. Hypoparathyroidism. N Engl J Med 2008;359:391-403
   PubMed Web of Science ®Google Scholar
• Cooper MS, Gittoes NJ. Diagnosis and management of hypocalcaemia. BMJ 2008;336:1298-302
   PubMed Web of Science ®Google Scholar
• Kim BG, Chang SK, Kim SM, et al. Dilated cardiomyopathy in a 2 month-old infant: a severe form of hypocalcemia with vitamin D deficient rickets. Korean Circ J 2010;40:201-3
   PubMedGoogle Scholar
• Tomar M, Radhakrishnan S, Shrivastava S. Myocardial dysfunction due to hypocalcemia. Indian Pediatr 2010;47:781-3
   PubMed Web of Science ®Google Scholar
• Gulley JL, Wu S, Arlen PM, et al. Persistent hypocalcemia induced by zoledronic acid in a patient with androgen-independent prostate cancer and extensive bone metastases. Clin Genitourin Cancer 2007;5:403-5
   PubMed Web of Science ®Google Scholar
• McCormick BB, Davis J, Burns KD. Severe hypocalcemia following denosumab injection in a hemodialysis patient. Am J Kidney Dis 2012;60:626-8
   PubMed Web of Science ®Google Scholar
• Mishra A. Symptomatic hypocalcemia following intravenous administration of zoledronic acid in a breast cancer patient. J Postgrad Med 2008;54:237
   PubMed Web of Science ®Google Scholar
• Segal E, Felder S, Haim N, et al. Vitamin D deficiency in oncology patients – an ignored condition: impact on hypocalcemia and quality of life. Isr Med Assoc J 2012;14:607-12
   PubMed Web of Science ®Google Scholar